GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » Cyclically Adjusted FCF per Share

BioLine Rx (XTAE:BLRX) Cyclically Adjusted FCF per Share : ₪-0.96 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BioLine Rx's adjusted free cash flow per share for the three months ended in Dec. 2023 was ₪0.017. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ₪-0.96 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 22.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of BioLine Rx was 22.30% per year. The lowest was 5.40% per year. And the median was 13.85% per year.

As of today (2024-05-01), BioLine Rx's current stock price is ₪0.176. BioLine Rx's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was ₪-0.96. BioLine Rx's Cyclically Adjusted Price-to-FCF of today is .


BioLine Rx Cyclically Adjusted FCF per Share Historical Data

The historical data trend for BioLine Rx's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Cyclically Adjusted FCF per Share Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.57 -2.04 -1.77 -1.33 -0.96

BioLine Rx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.33 -1.24 -1.12 -1.04 -0.96

Competitive Comparison of BioLine Rx's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, BioLine Rx's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Cyclically Adjusted Price-to-FCF falls into.



BioLine Rx Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioLine Rx's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.017/129.4194*129.4194
=0.017

Current CPI (Dec. 2023) = 129.4194.

BioLine Rx Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.478 99.695 -0.621
201406 -0.482 100.560 -0.620
201409 -0.363 100.428 -0.468
201412 -0.520 99.070 -0.679
201503 -0.318 99.621 -0.413
201506 -0.357 100.684 -0.459
201509 -0.324 100.392 -0.418
201512 -0.234 99.792 -0.303
201603 -0.295 100.470 -0.380
201606 -0.219 101.688 -0.279
201609 -0.198 101.861 -0.252
201612 -0.260 101.863 -0.330
201703 -0.482 102.862 -0.606
201706 -0.169 103.349 -0.212
201709 -0.229 104.136 -0.285
201712 -0.241 104.011 -0.300
201803 -0.243 105.290 -0.299
201806 -0.220 106.317 -0.268
201809 -0.210 106.507 -0.255
201812 -0.503 105.998 -0.614
201903 -0.131 107.251 -0.158
201906 -0.166 108.070 -0.199
201909 -0.155 108.329 -0.185
201912 -0.129 108.420 -0.154
202003 -0.143 108.902 -0.170
202006 -0.094 108.767 -0.112
202009 -0.069 109.815 -0.081
202012 -0.064 109.897 -0.075
202103 -0.042 111.754 -0.049
202106 -0.038 114.631 -0.043
202109 -0.026 115.734 -0.029
202112 -0.029 117.630 -0.032
202203 -0.029 121.301 -0.031
202206 -0.033 125.017 -0.034
202209 -0.044 125.227 -0.045
202212 -0.024 125.222 -0.025
202303 -0.033 127.348 -0.034
202306 -0.040 128.729 -0.040
202309 -0.040 129.860 -0.040
202312 0.017 129.419 0.017

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


BioLine Rx  (XTAE:BLRX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BioLine Rx Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx (XTAE:BLRX) Business Description

Industry
Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx (XTAE:BLRX) Headlines

From GuruFocus